Inman RD

ORCID: 0000-0002-4750-1422 · 1 paper in corpus

rct 2012

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study

Annals of the rheumatic diseases ·doi:10.1136/ard.2011.154799

OBJECTIVE: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. METHODS: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcut…